PharmaTher Files Patent Application In US For Psilocybin Drug Combination To Treat Neurological Disorders
PharmaTher Inc (CSE: PHRM) this morning announced that it has filed a provisional patent application with the US Patent and Trademark Office. The patent outlines the potential for a novel combination of FDA approved drugs and psilocybin for the treatment of neurological disorders.
The combinations filed were discovered utilizing the firms proprietary panaceAI drug repurposing AI platform, with the combinations said to combine with psilocybin to produce a therapeutic option that reduces the side effects and improves effectiveness of psilocybin in the treatment of neurological disorders.
PharmaTher then intends to partner with third party research organizations to conduct the required research and development of the formulations. The objective of the research is to complete investigational new drug-enabling studies, which gives the firm a leg-up in terms of clinical studies conducted through the US Food and Drug Administration.
“Since our inception we have been focused on developing an FDA-based product pipeline of novel uses of psychedelic pharmaceuticals, such as ketamine and psilocybin, and combinations with FDA approved drugs for neurological disorders. Expanding our intellectual property portfolio of psychedelic pharmaceuticals via the FDA approval pathway is the foundation of our business to protect our development and commercialization objectives and to increase shareholder value for the long-term.”
Fabio Chianelli, CEO of PharmaTher
PharmaTher last traded at $0.40 on the CSE.
FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
